Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

Description

Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).

Conditions

Interstitial Lung Disease, Pulmonary Hypertension

Study Overview

Study Details

Study overview

Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

Condition
Interstitial Lung Disease
Intervention / Treatment

-

Contacts and Locations

Phoenix

Pulmonary Associates, Phoenix, Arizona, United States, 85032

Hartford

Hartford Hospital, Hartford, Connecticut, United States, 06106

Lakeland

Lakeland Regional Health, Lakeland, Florida, United States, 33805

Naples

NCH Healthcare System, Naples, Florida, United States, 34102

Tampa

University of South Florida Health, Tampa, Florida, United States, 33606

Weston

Cleveland Clinic Florida, Weston, Florida, United States, 33331

Atlanta

Emory University Hospital, Atlanta, Georgia, United States, 30322

Austell

Piedmont Healthcare, Austell, Georgia, United States, 30106

Chicago

Loyola University Chicago, Chicago, Illinois, United States, 60153

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    United Therapeutics,

    Study Record Dates

    2025-06